ClinicalTrials.gg
CompletedNCT06648304Updated Feb 3, 2025

Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke

A Phase 3 interventional study of TTYP01 tablets and Placebo (Simulant TTYP01 Tablets) in Acute Ischemic Stroke, sponsored by Shanghai Auzone Biological Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Shanghai Auzone Biological Technology Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Apr 2023, registered Oct 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
614
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 750 studies in Ischemic Stroke with a site in China — 377 open to participants now, 396 under way, 76 of them phase 3. Ischemic Stroke · China.

Enrollment
152nd of 563
614 · median 266
Started
2023
with 91 others
Phase 3
109 of 750
63 open now
Registered
506th of 750
by date

Among the 750 studies in Ischemic Stroke with a site in China, this one is the 152nd largest by enrollment of the 563 interventional ones that give a count, is one of 92 that started in 2023, is one of 109 in phase 3, and was the 506th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

377 of the 750 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

372 more — sign in →

All 377 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 750 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

The study is designed as a multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy and safety of TTYP01 tablets in the treatment of acute ischemic stroke.

Read the detailed description

A multicenter, randomized, double-blind, parallel, placebo-controlled trial design is used to evaluate the efficacy and safety of TTYP01 tablets in the treatment of patients with acute ischemic stroke.

It is estimated that 618 patients will be enrolled and randomly assigned to the treatment group and the placebo control group in a 1:1 ratio, with 309 patients in each group. Normally, the duration of this study is approximately 90 days. This study will be divided into 2 periods, with a total of five visits: Treatment observation period: D1 \~ D28 (the minimum length of in-hospital observation will be not less than 7 days), including 3 visits (V1- V3); follow-up period: D29 \~ D90, including 2 visits (V4: D60 ± 5 for telephone follow-up; V5: D90 ± 5, returning to hospital for end-of-study visit).

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for enrollment in the study must meet all of the following inclusion criteria:

  1. Patients aged 18 \~ 80 years (both inclusive);
  2. Patients diagnosed with acute ischemic stroke according to the 2019AHA/ASA guidelines for ischemic stroke;
  3. Patients who do not accept suggestions of thrombolysis or thrombectomy or who do not meet the indications for these treatments;
  4. Patients with symptom onset within ≤ 24 hours; for wake-up strokes or when the exact time of symptom onset cannot be determined due to aphasia or disturbance of consciousness, the last time the patient is seen to be normal shall prevail;
  5. Patients who are having their first stroke or those who are experiencing a recurrence of stoke after a good recovery (mRS score of 0-1) from their most recent stroke;
  6. There are clear signs of neurological deficit: 6≤NIHSS score≤20, and also, the sum of NIHSS score for the 5th upper limb and the 6th lower limb is greater than or equal to 2.
  7. Subjects or their guardians are informed about the study, voluntarily agree to the participation, and provide written .

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study:

  1. Patients with any (such as metal implants like cardiac pacemakers, claustrophobia, etc.) that prevent them from undergoing CT or MRI examinations;
  2. Cranial CT or MRI confirmed intracranial hemorrhagic conditions, including but not limited to cerebral hemorrhage, epidural hematoma, subdural hematoma, intracranial hematoma, ventricular hemorrhage, subarachnoid hemorrhage, and traumatic cerebral hemorrhage; or cases of cerebral infarction with post-infarction hemorrhagic transformation. In cases of minor oozing, the investigator will determine eligibility for enrollment;
  3. Patients with massive cerebral infarction (low density > 1/3 of the cerebral hemisphere) as indicated by imaging examinations such as CT or MRI;
  4. Patients with cerebral infarction accompanied by disturbance of consciousness (NIHSS score Ia > 1 point), posterior circulation infarction, or (TIA);
  5. Patients with severe mental disorders, depression, or comorbid conditions affecting cognitive function, such as Alzheimer's disease, Parkinson's dementia, or Lewy body dementia, making them unable or unwilling to cooperate with the study;
  6. Patients who are scheduled for or have received intravenous thrombolysis, or who require endovascular treatment in the immediate or recent future (within 90 days);
  7. Patients with a history of brain malignant tumors or brain parasitic diseases;
  8. Patients with a history of severe craniocerebral injury or intracranial infection and an mRS score > 1 prior to this episode;
  9. Patients with severe hypertension (systolic blood pressure ≥ 220 mmHg or diastolic blood pressure ≥ 120 mmHg) that is uncontrolled by treatment before the first dose;
  10. Patients with blood glucose levels below 2.7 mmol/L without correction or above 22.2 mmol/L at the time of admission;
  11. Patients with dysphagia;
  12. Patients with a history of rheumatic heart disease or atrial fibrillation; those with a heart rate of less than 40 beats per minute or greater than 120 beats per minute; patients with second or third-degree heart block without a pacemaker or other malignant arrhythmias; and patients who have experienced acute myocardial infarction, cardiac intervention, or heart failure within the past 6 months (classified by the [NYHA] as III-IV).
  13. Patients with other serious systemic or organ diseases that the investigators believe may hinder the evaluation of efficacy or make it unlikely for the patient to complete the expected course of treatment and follow-up (such as malignant tumors with a of less than 3 months, etc.).;
  14. Patients with severe liver and kidney diseases or abnormal renal and liver function tests ( [ALT] or aspartate aminotransferase [AST] ≥ 3.0 times the [ULN]; serum creatinine [Cr] > 2.0 times the ULN);
  15. Patients with a bleeding tendency, including count (PLT) less than 75.0×10\^9/L, or severe bleeding within the 3 months prior to the onset of the disease.
  16. Patients with contraindications to antiplatelet therapy or statin therapy;
  17. Patients with allergic constitution, to Edaravone or its ;
  18. Patients with suspected or confirmed history of alcohol or drug abuse;
  19. Patients who are pregnant, lactating or have a recent pregnancy plan and are unwilling to use ;
  20. Patients who have participated in other clinical trials within 3 months or are participating in other clinical studies prior to this study;
  21. Patients who are deemed unsuitable by the investigator for participation in the clinical trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
614 participants (actual)

Study arms

  • Experimental
    TTYP01 tablets

    2 tablets (60 mg) of TTYP01, twice daily, administered 30\~60 minutes before breakfast and dinner

    Drug: TTYP01 tablets

  • Placebo comparator
    Placebo (Simulant TTYP01 Tablets)

    2 tablets (0 mg) of placebo, twice daily, administered 30\~60 minutes before breakfast and dinner

    Drug: Placebo (Simulant TTYP01 Tablets)

Interventions

  • Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (60 mg) of investigational drug each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).

  • DrugPlacebo (Simulant TTYP01 Tablets)

    Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (0 mg) of placebo each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with mRS score ≤1 on Day 90 of treatment.

    The mRS (modified Rankin Scale) is a scoring system used to assess the ability of post-stroke patients in their daily lives. It assesses the degree of functional impairment of patients after stroke through a standardized questionnaire, and is one of the most widely used tools for assessing the sequelae of stroke internationally. The MRS scores range from 0 to 5, with higher scores indicating more severe disability in patients.

    Time frame: 90 days after treatment initiation

Secondary outcomes

  1. mRS score on Day 90 of treatment

    The mRS (modified Rankin Scale) is a scoring system used to assess the ability of post-stroke patients in their daily lives. It assesses the degree of functional impairment of patients after stroke through a standardized questionnaire, and is one of the most widely used tools for assessing the sequelae of stroke internationally. The MRS scores range from 0 to 5, with higher scores indicating more severe disability in patients.

    Time frame: 90 days after treatment initiation

  2. Proportion of subjects with mRS score ≤2 on D90 of treatment

    The mRS (modified Rankin Scale) is a scoring system used to assess the ability of post-stroke patients in their daily lives. It assesses the degree of functional impairment of patients after stroke through a standardized questionnaire, and is one of the most widely used tools for assessing the sequelae of stroke internationally. The MRS scores range from 0 to 5, with higher scores indicating more severe disability in patients.

    Time frame: 90 days after treatment initiation

  3. Change from baseline in mRS score on D7, D28, D60 and D90 of treatment

    The mRS (modified Rankin Scale) is a scoring system used to assess the ability of post-stroke patients in their daily lives. It assesses the degree of functional impairment of patients after stroke through a standardized questionnaire, and is one of the most widely used tools for assessing the sequelae of stroke internationally. The MRS scores range from 0 to 5, with higher scores indicating more severe disability in patients.

    Time frame: Baseline and 7, 28, 60, 90 days after treatment initiation

  4. Change in NIHSS score from baseline on D7, D28 and D90 of treatment

    The NIHSS (National Institutes of Health Stroke Scale) is a standardized neurological examination tool used to assess neurological deficits in stroke patients. The scale consists of 15 tests and the total score is the sum of the individual scores ranges from 0 to 42, with lower scores indicating a better state of the patient.

    Time frame: Baseline and 7, 28, 90 days after treatment initiation

  5. Proportion of patients with NIHSS score improvement ≥ 4 points on D7, D28, and D90 of treatment

    The NIHSS (National Institutes of Health Stroke Scale) is a standardized neurological examination tool used to assess neurological deficits in stroke patients. The scale consists of 15 tests and the total score is the sum of the individual scores ranges from 0 to 42, with lower scores indicating a better state of the patient.

    Time frame: 7, 28 and 90 days after treatment initiation

  6. Proportion of subjects with NIHSS score of 0-1 on D7, D28 and D90 of treatment

    The NIHSS (National Institutes of Health Stroke Scale) is a standardized neurological examination tool used to assess neurological deficits in stroke patients. The scale consists of 15 tests and the total score is the sum of the individual scores ranges from 0 to 42, with lower scores indicating a better state of the patient.

    Time frame: 7, 28 and 90 days after treatment initiation

  7. Change in BI score from baseline on D7, D28 and D90 of treatment

    The BI (Barthel Index) is used to assess the patient's ability to perform activities of daily living and can be used to evaluate the patient's functional recovery before and after treatment, and it is one of the most widely used and researched methods of basic assessment of activities of daily living in clinical practice, with credible results. It is mainly based on the patient's actual daily performance and is not judged by the ability the patient may have. The BI scores range from 0 to 100, with higher scores indicating a better state of the patient.

    Time frame: Baseline and 7, 28, 90 days after treatment initiation

  8. Proportion of subjects with BI score ≥ 95 points on D7, D28 and D90 of treatment

    The BI (Barthel Index) is used to assess the patient's ability to perform activities of daily living and can be used to evaluate the patient's functional recovery before and after treatment, and it is one of the most widely used and researched methods of basic assessment of activities of daily living in clinical practice, with credible results. It is mainly based on the patient's actual daily performance and is not judged by the ability the patient may have. The BI scores range from 0 to 100, with higher scores indicating a better state of the patient.

    Time frame: 7, 28 and 90 days after treatment initiation

  9. MoCA score and comparison on D7, D28 and D90 of treatment

    The MoCA (Montreal Cognitive Assessment) Scale is a rating tool used to provide rapid screening for cognitive dysfunction. It includes 11 screening items in 8 cognitive domains: attention and concentration, executive function, memory, language, visual structural skills, abstract thinking, calculation and orientation. The total score is 30, with ≥26 being normal; the lower the score, the more severe the cognitive impairment.

    Time frame: 7, 28 and 90 days after treatment initiation

  10. HDRS score and comparison on D7, D28 and D90 of treatment

    The HDRS (Hamilton Depression Scale) was developed by Hamilton in 1960 and is the most commonly used scale for assessing depressive states in clinical settings. There are three versions of this scale: 17-item, 21-item and 24-item. The 21-item version was used for this Clinical Study, with a score range from 0 to 64. A score greater than 30 is severe depression, greater than 20 is moderate depression, and greater than 17 is mild depression.

    Time frame: 7, 28 and 90 days after treatment initiation

  11. Proportion of subjects with recurrent stroke within 90 days of treatment

    Time frame: within 90 days of treatment

  12. Changes in cranial MRI findings (infarct volume) relative to baseline

    Infarct volume will report in mm\^3

    Time frame: Baseline and 5, 28 days after treatment initiation

  13. Changes in cranial MRI findings (infarct area) relative to baseline

    Infarct area will report in mm\^2

    Time frame: Baseline and 5, 28 days after treatment initiation

07

Study locations

1 site
  • Daping Hospital
    Chongqing, Chongqing 400042, China
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jun 2024, 13 months.

Of 165 phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 18, 2024
StartActual
Apr 25, 2023
Primary completionActual
Jun 17, 2024
CompletionActual
Jun 17, 2024
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06648304
Lead sponsor
Shanghai Auzone Biological Technology Co., Ltd.
Responsible party
Sponsor
First posted
Oct 18, 2024
Start date
Apr 25, 2023
Primary completion
Jun 17, 2024
Completion
Jun 17, 2024
Last update
Feb 3, 2025

Study contacts

Yan-Jiang Wang, MD & PhD
principal investigator · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TTYP01

Start the discussion